Carvedilol reduces all-cause mortality versus β1-selective BBs in patients with systolic heart failure and AMI54
| Population | Trials | N | Results (RR, 95% CI) | p Value | NNT (12 month) |
|---|---|---|---|---|---|
| Systolic HF | 8 active-controlled | 4563 | 0.85 (0.78 to 0.93) | 0.0006 | 22 |
| AMI | 3 active-controlled | 644 | 0.55 (0.32 to 0.94) | 0.03 | 21 |
AMI, acute myocardial infarction; BB, β-blocker; HF, heart failure; NNT, number needed to treat; RR, relative risk.